BR0007627A - Mutações de hiv-1 selecionadas por beta-2', 3' -didehidro-2', 3' -didesóxi-5-fluorocitidina - Google Patents

Mutações de hiv-1 selecionadas por beta-2', 3' -didehidro-2', 3' -didesóxi-5-fluorocitidina

Info

Publication number
BR0007627A
BR0007627A BR0007627-9A BR0007627A BR0007627A BR 0007627 A BR0007627 A BR 0007627A BR 0007627 A BR0007627 A BR 0007627A BR 0007627 A BR0007627 A BR 0007627A
Authority
BR
Brazil
Prior art keywords
beta
hiv
d4fc
drug
didesoxy
Prior art date
Application number
BR0007627-9A
Other languages
English (en)
Inventor
Raymond F Schinazi
Dennis C Liotta
Jennifer Hammond
John W Mellors
Original Assignee
Univ Emory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Emory filed Critical Univ Emory
Publication of BR0007627A publication Critical patent/BR0007627A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MUTAçõES DE HIV-1 SELECIONADAS POR BETA-2',3'-DIDEHIDRO-2',3'-DIDESóXI-5-FLUOROCITIDINA". A presente invenção expõe um método para tratamento de HIV que compreende a administração de <225>-D-D4FC ou de seu sal farmaceuticamente aceitável ou uma pró-droga a um ser humano que necessite de terapia, em combinação ou alternação com uma droga que induz uma mutação no HIV-1 em uma localização diferente dos códons 70 (K a N), 90 ou 172 da região de transcriptase reversa. Também expõe um método para uso de <225>-D-D4FC com uma "terapia agressiva", em pacientes que exibem uma resistência medicamentosa a outros agentes anti-HIV. O <225>-D-D4FC pode ser usado, de modo geral, como terapia agressiva em qualquer paciente que exiba uma resistência a drogas que induzam a uma mutação em outros códons além dos 70 (K a N), 90 ou 172.
BR0007627-9A 1999-01-22 2000-01-21 Mutações de hiv-1 selecionadas por beta-2', 3' -didehidro-2', 3' -didesóxi-5-fluorocitidina BR0007627A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11677399P 1999-01-22 1999-01-22
PCT/US2000/001738 WO2000043014A2 (en) 1999-01-22 2000-01-21 Beta-d-2',3'-didehydro-2',3'-dideoxy-5-fluorocytidine for use in the treatment of hiv infections

Publications (1)

Publication Number Publication Date
BR0007627A true BR0007627A (pt) 2002-04-09

Family

ID=22369127

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0007627-9A BR0007627A (pt) 1999-01-22 2000-01-21 Mutações de hiv-1 selecionadas por beta-2', 3' -didehidro-2', 3' -didesóxi-5-fluorocitidina

Country Status (21)

Country Link
EP (1) EP1143976B9 (pt)
JP (1) JP2002535278A (pt)
KR (1) KR100745408B1 (pt)
CN (2) CN1337880A (pt)
AT (1) ATE324894T1 (pt)
AU (1) AU781281B2 (pt)
BR (1) BR0007627A (pt)
CA (1) CA2360039C (pt)
DE (1) DE60027691T2 (pt)
DK (1) DK1143976T3 (pt)
ES (1) ES2263449T3 (pt)
HK (1) HK1040064B (pt)
IL (1) IL144382A (pt)
MX (1) MXPA01007359A (pt)
NO (1) NO323586B1 (pt)
NZ (1) NZ528156A (pt)
PL (1) PL198237B1 (pt)
PT (1) PT1143976E (pt)
RU (1) RU2254133C2 (pt)
WO (1) WO2000043014A2 (pt)
ZA (1) ZA200105971B (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302779C (zh) * 2002-06-27 2007-03-07 美迪维尔公司 含有阿巴卡韦和阿洛夫定的药物制剂及其用途
WO2005055955A2 (en) * 2003-12-09 2005-06-23 Pharmasset, Inc. DOSING METHODS FOR ß-D-2’,3’-DIDEOXY-2’,3’-DIDEHYDRO-5-FLUOROCYTIDINE ANTIVIRAL THERAPY
WO2005097618A2 (en) 2004-04-01 2005-10-20 Achillion Pharmaceuticals, Inc. Low dose therapy for treating viral infections
CA2584670A1 (en) * 2004-10-19 2006-04-27 Achillion Pharmaceuticals, Inc. Combination therapy for treating viral infections
US8091224B2 (en) * 2008-10-06 2012-01-10 GE Intelligent Platforms Embedded Systems, Inc. Method for coupling a battery within an embedded system

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL8901258A (nl) * 1989-05-19 1990-12-17 Stichting Rega V Z W 5-halogeno-2',3'-dideoxycytidinederivaten in geneesmiddelen voor het behandelen van retrovirus-infecties.
FR2729390A1 (fr) * 1995-01-18 1996-07-19 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US5703058A (en) * 1995-01-27 1997-12-30 Emory University Compositions containing 5-fluoro-2',3'-didehydro-2',3'-dideoxycytidine or a mono-, di-, or triphosphate thereof and a second antiviral agent
US5869461A (en) * 1995-03-16 1999-02-09 Yale University Reducing toxicity of L-nucleosides with D-nucleosides
MXPA00012842A (es) * 1998-06-24 2004-06-22 Univ Emory Uso de 3'-azido-2',3'-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.

Also Published As

Publication number Publication date
DK1143976T3 (da) 2006-09-04
KR100745408B1 (ko) 2007-08-02
RU2254133C2 (ru) 2005-06-20
WO2000043014A3 (en) 2000-11-30
CA2360039A1 (en) 2000-07-27
EP1143976A2 (en) 2001-10-17
HK1040064A1 (en) 2002-05-24
NO20013599L (no) 2001-09-20
JP2002535278A (ja) 2002-10-22
NO20013599D0 (no) 2001-07-20
ATE324894T1 (de) 2006-06-15
PT1143976E (pt) 2006-09-29
IL144382A0 (en) 2002-05-23
NZ528156A (en) 2005-03-24
CN101219148A (zh) 2008-07-16
CA2360039C (en) 2009-11-24
WO2000043014A2 (en) 2000-07-27
EP1143976B9 (en) 2007-02-14
ES2263449T3 (es) 2006-12-16
IL144382A (en) 2007-02-11
AU781281B2 (en) 2005-05-12
CN1337880A (zh) 2002-02-27
HK1040064B (zh) 2006-07-21
DE60027691D1 (de) 2006-06-08
WO2000043014A8 (en) 2001-01-18
KR20020068260A (ko) 2002-08-27
NO323586B1 (no) 2007-06-11
PL198237B1 (pl) 2008-06-30
ZA200105971B (en) 2002-10-21
MXPA01007359A (es) 2003-09-22
EP1143976B1 (en) 2006-05-03
DE60027691T2 (de) 2007-04-12
AU2627000A (en) 2000-08-07

Similar Documents

Publication Publication Date Title
MXPA00012842A (es) Uso de 3&#39;-azido-2&#39;,3&#39;-didesoxiuridina en combinacion de drogas adicionales contra el vih para la manufactura de un medicamento para el tratamiento del vih.
HUP0300027A2 (en) Nucleoside analogs with carboxamidine modified monocyclic base and process for their use
UA40589C2 (uk) Спосіб лікування людини, що страждає від вірусної інфекції, фармацевтична композиція, комбінація речовин для отримання ліків та фармацевтична комбінація
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
NL970006I2 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
BG104984A (en) 3-(amino- or aminoalkyl)pyridinone derivatives and their use for the treatment of hiv related diseases
JP2002528502A5 (pt)
KR880007079A (ko) 레트로비루스에 감염된 환자치료에 있어서의 3&#39;-디옥시티미딘-2&#39;-엔(3&#39;-디옥시-2&#39;,3&#39;-디디하이드로티미딘)의 사용법
EA200000176A1 (ru) Применение физиологически приемлемых соединений, солей и комплексов ванадия
DK416089D0 (da) Heparinfragmenter og -fraktioner med anti-hiv virkning
BR0007627A (pt) Mutações de hiv-1 selecionadas por beta-2&#39;, 3&#39; -didehidro-2&#39;, 3&#39; -didesóxi-5-fluorocitidina
GB9023701D0 (en) Medical treatment
ATE192926T1 (de) Flavopereirine enthaltende zusammensetzung und ihre anwendung in der behandlung gegen hiv-viren
ATE297732T1 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
KR910018393A (ko) 항바이러스제로서의 비대칭 2-(포스포노메톡시)프로필 구아닌
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법
EP1731155A3 (en) Beta-d-2&#39;, 3&#39; -didehydro-2&#39;, 3&#39; -dideoxy-5-fluorocytidine for use in the treatment of hiv infections
DE60025826D1 (de) Pyrazolidinol-verbindungen
WO1990005523A3 (en) Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase
KR930702985A (ko) 식도암의 치료
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
James PMPA--first human results
JPS62265227A (ja) 薬剤性末梢神経障害の予防・治療剤
Hargrave et al. 5, 11-dihydro-6 H-dipyrido (3, 2-B: 2, 3'-E)(1, 4) diazepines and their use in the prevention or treatment of HIV infection
GEP20043356B (en) Compounds Useful For Treatment or Prevention of Diseases Mediated By Alpha- 2B-Adrenoceptor

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE A61K 31/513, A61P 31/18

Ipc: A61K 31/513 (2009.01), A61P 31/18 (2009.01), C12N

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O, 13, 24 E 25 DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.